Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04704232
Recruitment Status : Recruiting
First Posted : January 11, 2021
Last Update Posted : January 22, 2021
Sponsor:
Information provided by (Responsible Party):
AlzeCure Pharma

Brief Summary:
Phase 1 b placebo-controlled study in healthy volunteers to study safety, efficacy and pharmacokinetics of Topical ACD440 on normal skin, skin optimized for penetration and skin exposed to ultraviolet radiation

Condition or disease Intervention/treatment Phase
Pain Drug: ACD440 Phase 1

Detailed Description:
This is an exploratory study, no primary or secondary endpoints are being defined.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective,Double-blind,Randomized,Placebo-controlled Study of Safety,Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers
Estimated Study Start Date : January 2021
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Active Comparator: ACD440 Drug: ACD440
Double blind, parallel within subject comparison

Placebo Comparator: Placebo Drug: ACD440
Double blind, parallel within subject comparison




Primary Outcome Measures :
  1. Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs [ Time Frame: 5 Days ]
    Not defined as primary as per protocol, but system does not seem to allow omittance of primaries


Other Outcome Measures:
  1. Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs [ Time Frame: 5 days ]
    Exploratory efficacy endpoint

  2. Visual analog scale rating of laser induced pain [ Time Frame: 5 days ]
    Exploratory efficacy endpoint

  3. Number and percentage of subjects with adverse events [ Time Frame: 5 days ]
    Safety endpoint

  4. Number and percentage of subjects with clinically significant changes in 12-lead ECGs, vital signs and laboratory findings [ Time Frame: 5 days ]
    Safety endpoint



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteer
  • Fitzpatrick skin type II or III
  • Women not childbearing potential or highly effective contraception

Exclusion Criteria:

  • Pregnancy, lactation
  • Drug abuse
  • Clinically significant illness
  • Positive COVID 19 test at screening or COVID 19 infection in the past

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04704232


Contacts
Layout table for location contacts
Contact: Johan Sandin, CSO +46703738824 info@alzecurepharma.com

Locations
Layout table for location information
Sweden
AlzeCure Pharma investigational site Recruiting
Stockholm, Sweden
Contact: Johan Sandin, PhD       info@alzecurepharma.com   
Sponsors and Collaborators
AlzeCure Pharma
Layout table for additonal information
Responsible Party: AlzeCure Pharma
ClinicalTrials.gov Identifier: NCT04704232    
Other Study ID Numbers: D8000CI-001
First Posted: January 11, 2021    Key Record Dates
Last Update Posted: January 22, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No